Table 1.

Baseline demographics, causes of kidney disease, myocardial status, and medication usage of patients randomized to lifestyle intervention or control groups that completed a 12-month follow-up visit

Lifestyle Intervention Group (n=36)Control Group (n=36)Lost to Follow-Up (n=11)
Women12 (33)15 (42)6 (45)
Age (yr)60.2±9.762.0±8.454.4±10.1
eGFR (ml/min per 1.73 m2)38.4±8.839.4±8.942.0±8.7
Cause of CKD
 Diabetes9 (25)11 (30)4 (36)
 Renovascular6 (17)5 (14)
 GN10 (28)11 (30)3 (27)
 APKD3 (8)1 (9)
 Other11 (30)6 (17)3 (27)
Risk factors
 Type 2 diabetes15 (42)15 (42)3 (27)
 Current smoker5 (14)3 (8)3 (27)
 Previous myocardial infarction5 (14)7 (24)
 Systolic dysfunction 4 (11)2 (5)
 Diastolic dysfunction 19 (56)25 (78)3 (27)
Medications
 ACEi17 (47)19 (54)6 (55)
 ARB22 (61)20 (56)5 (45)
 β blocker14 (39)15 (42)
 Calcium blocker10 (28)17 (47)3 (27)
 Platelet inhibitor19 (53)14 (39)1 (9)
 Statin23 (64)24 (67)5 (45)
 Insulin9 (25)10 (28)1 (9)
  • Values are mean ± SD for normally distributed values, or n (%) for categorical variables. There were no significant differences (P>0.05 for all) between groups at baseline. eGFR, estimated GFR; APKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.